期刊文献+

重组人血管内皮抑制素联合顺铂对人骨肉瘤MG-63细胞VEGF基因表达、增殖及侵袭力的影响 被引量:1

Effects of recombinant human vascular endostatin combined with cisplatin on the expression of VEGF and the proliferation and invasion ability of MG-63 osteosarcoma cells in vitro
下载PDF
导出
摘要 目的观察重组人血管内皮抑制素(rh Endo)联合顺铂对人骨肉瘤MG-63细胞VEGF基因表达、增殖及侵袭力的影响。方法顺铂、rh Endo、rh Endo联合顺铂分别处理MG-63细胞,采用RT-PCR和Western blot检测细胞VEGF mRNA和蛋白表达量,CCK-8实验检测细胞增殖,流式细胞术检测细胞凋亡,Transwell小室体外迁移实验检测细胞侵袭和迁移能力。结果 rh Endo联合顺铂组对VEGF mRNA和蛋白表达量、细胞增殖、侵袭迁移的抑制作用以及对细胞凋亡的促进作用均显著高于rh Endo、顺铂单药组,差异有统计学意义(P<0.05)。结论重组人血管内皮抑制素联合顺铂能够在抑制骨肉瘤MG-63细胞VEGF表达、细胞增殖和侵袭力、促进细胞凋亡方面发挥协同作用。 Objective To investigate the effects of recombinant human vascular endostatin( rh Endo) combined with cisplatin on the expression of vascular endothelial cell growth factor( VEGF) and proliferation and invasion ability of MG-63 osteosarcoma cells in vitro. Methods MG-63 cells were treated by cisplatin,rh Endo or rh Endo combined with cisplatin,respectively. The expression levels of VEGF mRNA and protein were detected by Western Blot,and the proliferation,apoptosis and invasion ability of osteosarcoma cells were detected by CCK-8 test,flow cytometry and Transwell invasion assay,respectively. Results The expression levels of VEGF mRNA and protein,cell apoptotic rate,the inhibitory effect on cell proliferation and invasion ability in rh Endo combined with cisplatin group were significantly increased,as copmpared with those in simple rh Endo group or simple cisplatin group( P〈 0. 05). Conclusion The rh Endo combined with cisplatin can inhibit the expression of VEGF and proliferation and invasion ability of MG-63 osteosarcoma cells,and can promote cell apoptosis,with a synergetic effect.
作者 张黎明
出处 《河北医药》 CAS 2015年第12期1785-1788,共4页 Hebei Medical Journal
关键词 重组人血管内皮抑制素 人骨肉瘤细胞 VEGF 增殖 侵袭转移 recombinant human vascular endostatin human osteosarcoma cell vascular endothelial growth factor proliferation invasion and metastasis
  • 相关文献

参考文献13

  • 1Botter SM,Neri D,Fuchs B. Recent advances in osteosarcoma. Curr Opin Phannaeol,2014,16C : 15-23.
  • 2Zbuang Y, Wei M. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a recta-analysis. Tumour Bio1,2014,35 : 1745-1749.
  • 3Xu M, Xu CX, Bi WZ, et al. Effects of endostar combined muhidmg chemotherapy in osteosarcoma. Bone ,2013,57:111-115.
  • 4Kim HJ, Cbalmers PN, Morros CD. Pediatric osteogenie sarcoma. Curt Opin Pediatr ,2010,22:61-66.
  • 5Brand RA. 50 years ago in CORR: the present trend in treatment of os- teogenie sarcoma. Clin Orthop Relat ReS,2009,467 : 3038-3039.
  • 6Messerschmitt PJ,Gareia RM, Abdulkarim FW, et al. Osteosareoma. J Am Acad Orthopaed Surg,2009 ,17 :515-527.
  • 7Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat,2010, 13 : 16-28.
  • 8Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer,2002,86 : 864-869.
  • 9Kaya M, Wada T, Nagoya S,et al. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci ,2007,12 : 562-567.
  • 10Maae E, 01sen DA, Steffensen KD,et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat,2012,133: 257-265.

同被引文献25

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部